Andrew Hirsch Named Chief Executive Officer of C4 Therapeutics

WATERTOWN, Mass, September 8, 2020 – C4 Therapeutics, Inc. (C4T), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins through degradation, today announced the hiring of Andrew Hirsch as the Company’s incoming chief executive officer. Mr. Hirsch comes to C4T from Agios Pharmaceuticals where he was chief financial officer…

C4 Therapeutics Announces the Additions of William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer

WATERTOWN, Mass, July 15, 2020 – C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the addition of William McKee and Jolie M. Siegel to its leadership team as Chief Financial Officer and Chief Legal Officer, respectively. Mr. McKee currently also…

C4 Therapeutics Raises $170 Million Financing to Bring Robust Pipeline of Protein Degraders to Clinical Proof-of-concept and to Advance Proprietary Platform

–Multiple oncology-focused programs poised to enter clinical trials in 2021 and 2022– WATERTOWN, Mass, June 16, 2020 – C4 Therapeutics, Inc. (C4T), a biotechnology company pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation, today announced the closing of a $170 million financing, including $150 million in Series B equity co-led by existing…

C4 Therapeutics Announces the Addition of Ryan B. Corcoran, M.D., Ph.D. to the Scientific Advisory Board (SAB)

WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced the appointment of Ryan B. Corcoran, M.D., Ph.D., to the Company’s Scientific Advisory Board (SAB). “C4 Therapeutics has established a scientific advisory board of leading researchers and physicians and are excited to expand that expertise with the addition of Ryan Corcoran, a world leader in oncogenic signaling pathways,” said Andy…

C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-based Medicines with Roche

WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. “We are excited to see our partnership with Roche evolve and further accelerate our efforts to bring degrader-based medicines into the clinic,” said Andrew…

Biogen and C4 Therapeutics Enter into Strategic Collaboration to Discover and Develop Potential New Treatments for Neurological Conditions

C4T’s targeted protein degradation platform provides a novel approach to neuroscience drug discovery and development, complementing Biogen’s broader research and development efforts across multiple modalities CAMBRIDGE and WATERTOWN, Mass. – Biogen Inc (Nasdaq: BIIB) and C4 Therapeutics (C4T) announced today that they have entered into a strategic collaboration to investigate the use of C4T’s novel protein degradation…

C4 Therapeutics Announces Appointment of Andrew Phillips, Ph.D. As President and Chief Executive Officer

WATERTOWN, Mass. – C4 Therapeutics (C4T) today announced that Andrew Phillips, Ph.D. has been appointed as President and Chief Executive Officer. Dr. Phillips has been leading C4T’s scientific efforts as Chief Scientific Officer since January 2016 and assumed corporate leadership responsibilities with his added appointment as President in September 2016. In conjunction with Dr. Phillips…